Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT06252129
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Subjects undergoing a lung specimen lymph node dissection — OTHER
    A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team. The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging.
  • Control group — OTHER
    Control group

Study Details

Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.

Key Dates

Start date
Jul 26, 2024
Status verified
Mar 2026
Primary completion
Jan 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
160 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: 1. Interventional group
    subjects who are being consented to this study and undergoing lymph node dissection as outlined in this protocol
  • No Intervention: Concurrent non-interventional group
  • Other: Retrospective cohort from 2021-2020

Primary Outcome Measure

Number of lymph nodes sampled [ Time Frame: 2 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Womens HospitalBostonMassachusetts02115
Paula Ugalde Figueroa THORACIC SURGEON, MD
[email protected]
617-794-6491

Find similar trials in Boston, MA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Brigham and Womens Hospital· Boston, MA

Related Studies